Indications and Usage Mechanisms of Action Clinical Research Binding Mode
ChemicalBook > CAS DataBase List > Selumetinib

Selumetinib

Indications and Usage Mechanisms of Action Clinical Research Binding Mode
Product Name
Selumetinib
CAS No.
606143-52-6
Chemical Name
Selumetinib
Synonyms
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide;6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide;113183;CS-1912;AZD 6244;AZD-6224;umetinib;Smetinib;ARRY 142886;Selumetinib
CBNumber
CB81871940
Molecular Formula
C17H15BrClFN4O3
Formula Weight
457.68
MOL File
606143-52-6.mol
More
Less

Selumetinib Property

Melting point:
>219°C (dec.)
Density 
1.69
storage temp. 
-20°
solubility 
Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 2 mg/ml)
form 
Beige powder.
pka
14.20±0.10(Predicted)
color 
White
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months.
More
Less

Safety

HS Code 
29349990
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H317May cause an allergic skin reaction

H318Causes serious eye damage

H373May cause damage to organs through prolonged or repeated exposure

Precautionary statements

P262Do not get in eyes, on skin, or on clothing.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P312Call a POISON CENTER or doctor/physician if you feel unwell.

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
11599
Product name
AZD 6244
Purity
≥98%
Packaging
10mg
Price
$32
Updated
2024/03/01
Cayman Chemical
Product number
11599
Product name
AZD 6244
Purity
≥98%
Packaging
25mg
Price
$55
Updated
2024/03/01
Cayman Chemical
Product number
11599
Product name
AZD 6244
Purity
≥98%
Packaging
50mg
Price
$86
Updated
2024/03/01
Cayman Chemical
Product number
11599
Product name
AZD 6244
Purity
≥98%
Packaging
100mg
Price
$109
Updated
2024/03/01
Tocris
Product number
6815
Product name
Selumetinib
Purity
≥98%(HPLC)
Packaging
50
Price
$91
Updated
2021/12/16
More
Less

Selumetinib Chemical Properties,Usage,Production

Indications and Usage

Selumetinib, 1 has a chemical name of 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide. It was developed by British company AstraZeneca and is used to treat advanced non-small cell lung cancer (NSCLC). It is mainly used to treat bile duct cancer, colon cancer, NSCLC, etc. Currently, Selumetinib is in stage III clinical trials for treatment of NSCLC.

Mechanisms of Action

Selumetinib is the first mitogenextracellular kinase (MEK1/2) inhibitor to be used in thyroid cancer clinical trials. It inhibits extracellular signal regulating kinase (ERK/2) and activates caspase to dramatically inhibit ERK1/2 phosphorylation.

Clinical Research

In phase II clinical trials of radioiodine-refractory papillary thyroid carcinoma, 39 patients took daily oral doses of Selumetinib (100mg bid) for 28 days; results showed that 21 patients’ conditions stabilized (54%), 11 patients’ conditions worsened (28%), 49% patients’ conditions were stable for 16 weeks, 36% patients’ conditions were stable for 24 weeks, and survival terms did not progress to 32 weeks. Negative reactions mainly consisted of rashes (59%), diarrhea (44%), and weakness (41%). Some studies found that after treating 20 patients with thyroid cancer with Selumetinib (75mg bid) for 4 weeks, Selumetinib increased the iodine uptake and retention of patients with radioiodine-refractory papillary thyroid carcinoma. In a blind and random comparative study between a Selumetinib and Docetaxel (DOC) combination treatment group and DOC and placebo treatment group for 87 mutant NSCLSC patients, survival times were 9.4 months and 5.2 months, PFS were 5.3 months and 2.1 months, RR were 37% and 0%, thus showing dramatic differences. Selumetinib’s main negative reactions include neutrophil depletion, dermatitis, and respiratory failure.

Binding Mode

In the co-crystal structure of selumetinib in complex with MEK1 and AMP–PNP (Fig. 3), selumetinib binds to a unique and specific allosteric pocket on the N-terminal domain of MEK1, next to a typical ATP-binding site. This binding results in a conformational change, which prevents the RAF-induced phosphorylation, and locks MEK1/2 into a catalytically inactive state, thereby blocking the RAS signaling. The imine nitrogen of the benzo[d]imidazole core hydrogen bonds to the amide NH of Ser212, and the three oxygen atoms of the amide side chain form three hydrogen bonds with the primary amine of Lys97. In addition, the terminal hydroxyl group hydrogen bonds to the α-phosphoryl oxygen of AMP–PNP (Fig. 4).

Description

Selumetinib (AZD6244; ARRY-142886) is an oral MEK inhibitor. In a randomized trial, NSCLC patients with wild-type KRAS were randomized to erlotinib alone or combination therapy with selumetinib, while mutant KRAS patients were randomized to selumetinib alone or combination therapy. The primary end points were PFS for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Results were not impressive, with no PFS difference in the KRAS wild-type arm (2.4 vs. 2.1?months) and no ORR difference in the KRASmutated subgroup (0% vs. 10%). A planned trial of selumetinib in combination with the anti-PD-L1 antibody durvalumab has since been suspended (NCT03004105).

Uses

It is a tight-binding, uncompetitive inhibitor of mitogen-activated protein kinase kinases (MEK) 1 and 2 currently in clinical development. It is useful as biomarker in human lung cancer cell. Potent MEK inhibitor.

Definition

ChEBI: A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectiv ly. It is a MEK1 and MEK2 inhibitor.

brand name

Koselugo

General Description

Class: dual threonine/tyrosine kinase; Treatment: children with NF1; Other name: AZD-6244, ARRY-142886; Oral bioavailability = 62%; Elimination half-life = 6.2 h; Protein binding = 97.7%

target

MEK1

Metabolism

Following oral administration of radiolabeled selumetinib, the most prominent drug-related component in the plasma was selumetinib, accounting for 40% of the plasma radioactivity. The major circulating metabolite was an amide glucuronide 2, which accounted for 22% of the plasma radioactivity. This metabolite resulted from loss of the ethanediol moiety to give the primary amide 1, which underwent glucuronidation and an additional loss of 2 mass units, most likely due to further oxidation of the N-methylbenzimidazole moiety (Fig. 5).

storage

Store at -20°C

Dosage

Selumetinib is characterized by a moderate oral bioavailability (62%) and a relatively short half-life (6.2 h), and these properties contribute to twice-daily dosing regimen (25 mg dosage).

References

1) Davies?et al. (2007),?AZD6244(ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamics relationship, and potential for combination in preclinical models; Mol. Cancer Ther.,?6?2209 2) Yeh?et al. (2007),?Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor; Clin. Cancer Res.,?13?1576 3) Catalanotti?et al. (2013),?Phase II trial of MEK inhibitor selumetinib(AZD6244) in patients with BRAFV600E/K-mutated melanoma; Clin. Cancer Res.,?19?2257 4) O’Neil?et al. (2011),?Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma; J. Clin. Oncol.,?29?2350 5) Khurum?et al. (2012),?A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244)(MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors; J. Clin. Oncol.,?30?e13599 6) Hainsworth?et al. (2010),?A phase II, open label, randomized study to assess the efficacy and safety of AZD6244 versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens; J. Thorac. Oncol.,?5?1630 7) Bodoky?et al. (2012),?A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy; Invest. New Drugs,?30?1216

Selumetinib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Selumetinib Suppliers

Canada 1 China 279 China Hong Kong 1 Germany 1 India 4 The Netherlands 1 United Kingdom 4 United States 28 Global 319
MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
Musechem
Tel
+1-800-259-7612
Fax
+1-800-259-7612
Email
info@musechem.com
Country
United States
ProdList
4660
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32165
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Cckinase, Inc.
Tel
+1 (732)236-3202
Email
sales@cckinase.com
Country
United States
ProdList
2738
Advantage
58
BOC Sciences
Tel
+1-631-485-4226
Fax
1-631-614-7828
Email
inquiry@bocsci.com
Country
United States
ProdList
19553
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
TargetMol Chemicals Inc.
Tel
Email
support@targetmol.com
Country
United States
ProdList
38632
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
BOC Sciences
Tel
16314854226
Email
info@bocsci.com
Country
United States
ProdList
9923
Advantage
65
Alfa Chemistry
Tel
--
Fax
--
Email
info@Alfa-Chemistry.com
Country
United States
ProdList
6814
Advantage
0
Focus Biomolecules
Tel
--
Fax
--
Email
sales@focusbiomolecules.com
Country
United States
ProdList
1284
Advantage
58
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
LC Laboratories
Tel
--
Fax
--
Email
custserv@lclabs.com
Country
United States
ProdList
503
Advantage
50
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80
Creative Enzymes
Tel
--
Fax
--
Email
info@creative-enzymes.com
Country
United States
ProdList
6057
Advantage
58
ChemShuttle. Inc.
Tel
--
Fax
--
Email
Sales@ChemShuttle.com
Country
United States
ProdList
6695
Advantage
58
Axon Medchem LLC
Tel
--
Fax
--
Email
info@axonmedchem.com
Country
United States
ProdList
763
Advantage
58
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
Active Biopharma Corp
Tel
--
Fax
--
Email
support@activebiopharma.com
Country
United States
ProdList
82
Advantage
0
ChemieTek
Tel
--
Fax
--
Email
info@chemietek.com
Country
United States
ProdList
219
Advantage
50
Selleck Chemicals LLC
Tel
--
Fax
--
Email
info@selleckchem.com
Country
United States
ProdList
824
Advantage
60
LKT Laboratories, Inc.
Tel
--
Fax
--
Email
info@lktlabs.com
Country
United States
ProdList
2164
Advantage
64
Tinib-Tools
Tel
--
Fax
--
Country
United States
ProdList
164
Advantage
0
AK Scientific, Inc.
Tel
--
Fax
--
Email
sales@aksci.com
Country
United States
ProdList
6347
Advantage
65
Santa Cruz Biotechnology, Inc.
Tel
--
Fax
--
Email
scbt@scbt.com
Country
United States
ProdList
3597
Advantage
60
More
Less

View Lastest Price from Selumetinib manufacturers

Cangzhou Kangrui Pharma Tech Co. Ltd.,
Product
Selumetinib 606143-52-6
Price
US $0.00-0.00/g
Min. Order
10g
Purity
99%
Supply Ability
1kg
Release date
2024-10-17
Zhengzhou Anbu Chem Co.,Ltd
Product
Selumetinib 606143-52-6
Price
US $0.00/KG
Min. Order
1KG
Purity
98%
Supply Ability
1000KGS
Release date
2023-06-19
Hebei Weibang Biotechnology Co., Ltd
Product
Selumetinib 606143-52-6
Price
US $10.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
10 mt
Release date
2021-08-06

606143-52-6, SelumetinibRelated Search:

AP26113 Lenvatinib Afatinib (BIBW 2992) Vandetanib AZD-6244 O-(2-(vinyloxy)ethyl)hydroxylamine Bortezomib MK-2206 2HCl PD 0325901 Trametinib Erlotinib hydrochloride PLX4032 LOXO-292 Ceritinib (LDK378) Cabozantinib WZ4002 Dabrafenib Dacomitinib (PF299804)

  • ARRY 142886
  • AZD 6244
  • 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
  • 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
  • Selumetinib AZD624
  • 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-car
  • Selumetinib, 99%, a highly selective MEK1 inhibitor
  • Selumetinib, Free BaseAZD6244ARRY-142886
  • Selumetinib (AZD6244) Selumetinib
  • ARRY-142886; SELUMETINIB;AZD-6244;ARRY142886
  • AZD6244 (ARRY142886, Selumetinib)
  • AZD6244 (Selumetinib,ARRY-142886)
  • 113183
  • CS-1912
  • Selumetinib Base
  • Selumetinib
  • 5-(4-Bromo-2-chlorophenylamino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide
  • 6-(4-Bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide
  • SeluMatinib(5-[(4-BroMo-2-chlorophenyl)aMino]-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benziMidazole-6-carboxaMide
  • AZD6244(SeluMetinib)
  • AZD6244; ARRY142886
  • SeluMetinib (AZD6244)
  • Array142886
  • AZD-6244(SeluMetinib)/AZD6244
  • 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carbox
  • AZD6244, ARRY-142886, ARRY-886
  • 5-(4-BroMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benziMidazole-6-carbohydroxaMic acid 2-hydroxyethyl ester
  • 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide Selumetinib (AZD6244)
  • AZD 6244 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
  • selumetinib (MEK inhibitor)
  • Selumetinib, >=98%
  • AZD-6224
  • umetinib
  • umetinib (AZD6244) SeL
  • 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-
  • Selumetinib USP/EP/BP
  • Selumetinib D4
  • 5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzodimidazol-6-carboxamide
  • Selumetinib API
  • Smetinib
  • Quinoxyfen Impurity 1
  • 606143-52-6
  • 60614-52-6
  • C17H15BrClFN4O3
  • MAPK
  • Inhibitors
  • Antineoplastic
  • apis
  • Aromatics
  • Heterocycles
  • Inhibitor
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • API
  • Research